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Abstract In children with chronic kidney disease (CKD)
optimal control of mineral and bone disorder (MBD) is essen-
tial not only for the prevention of debilitating skeletal compli-
cations and for achieving adequate growth, but also for pre-
serving long-term cardiovascular health. The growing skele-
ton is particularly vulnerable to the effects of CKD, and bone
pain, fractures and deformities are common in children on
dialysis. Defective bone mineralisation has been linked with
ectopic calcification, which in turn leads to significant mor-
bidity and mortality. Despite national and international guide-
lines for the management of CKD-MBD, the management of
mineral dysregulation in CKD can be extremely challenging,
and a significant proportion of patients have calcium, phos-
phate or parathyroid hormone levels outside the normal
ranges. Clinical and experimental studies have shown that,
in the setting of CKD, low serum calcium levels are associated
with poor bone mineralisation, whereas high serum calcium
levels can lead to arterial calcification, even in children. The
role of calcium in CKD-MBD is the focus of this review.
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Introduction
Hyperphosphataemia is prevalent in chronic kidney disease
(CKD), and particularly so in patients on dialysis. Phosphate
retention causes hyperparathyroidism and bone disease, and is
also a potent vascular toxin in its own right, as well as through
its effects on parathyroid hormone (PTH) and fibroblast
growth factor 23 (FGF23) [1, 2]. Phosphate control begins
with dietary restriction, but as CKD becomesmore severe, this
is rarely adequate and phosphate binders become necessary.
Unfortunately, compliance with phosphate binders is poor [3]
due to their side effects and to the repetitive monotony of the
need for their ingestion with every meal and snack.
Phosphate binders are categorised according to
whether they are calcium based or calcium-free. There
is an ongoing market for non-calcium-containing
binders, with new ones currently on trial. The driving
force behind this search is (1) the recognition that
phosphate control is difficult and remains poor and (2)
the relationship between gastrointestinal absorption and
retention of calcium excess, and vascular calcification
that has been demonstrated in adults. However, only
calcium carbonate (CaCO3) and acetate are licensed in
children, along with sevelamer hydrochloride for those
aged >12 years.
The growing skeleton is particularly vulnerable to the
effects of CKD-mineral and bone disorder (MBD) as calcium
accrual in the skeleton continues from birth until peak bone
mass is reached at approximately 30 years of age [4]. How-
ever, high calcium levels can lead to arterial calcification, even
in children [5, 6]. In adults receiving dialysis, randomised
trials have shown that the progression of calcification is great-
er with calcium acetate than with the calcium-free binder
sevelamer [7–9]. These studies have led to recommendations
to restrict the use of calcium-based phosphate binders. Impor-
tantly, the average age of patients in these studies was 65 years,
with many being post-menopausal. While data from adult
CKD studies should not be extrapolated to paediatric practice,
many paediatricians are increasingly using calcium-free phos-
phate binders in children. In this review we discuss the role of
calcium in CKD-MBD, including calcium homeostasis and
the relative merits of different phosphate binders.
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How good are paediatric nephrologists at controlling
calcium and phosphate levels in their patients?
Despite national and international guidelines for the
management of CKD, many patients have CKD-MBD
[10–13]. This is exemplified by data from the Interna-
tional Pediatric Peritoneal Dialysis Network (IPPN) in
153 children worldwide, in whom the PTH varied from
country to country, but overall was over fivefold the
upper limit of normal in approximately 50 % of pa-
tients. The highest levels were associated with high
phosphate and lower calcium levels [14]. This level of
PTH is associated with symptomatic bone disease: of
nearly 900 children in the IPPN, 1.5 % have active
bone pain, 5 % limb deformities, 10 % radiological
osteodystropy and 5 % osteopaenia [3]. The latest IPPN
data shows that for all ages, 14 % of patients have a
serum calcium level below the normal range, 24 % have
a serum phosphate level above the normal range, 47 %
have a serum PTH level above the normal range; in
addition, although 21 % are on sevelamer, 22 % are on
a calcium supplement other than a calcium-containing
phosphate binder [15]. In a cohort of 249 young Dutch
adults with onset of end-stage kidney disease (ESKD)
before the age of 14 years, 61 % had severe growth
retardation, 37 % had bone disease (defined by at least
one of the following conditions: deforming bone abnor-
malities, chronic pain related to the skeletal system,
disabling bone abnormalities, aseptic bone necrosis and
atraumatic fractures) and 18 % had disabilities resulting
from bone impairment [16].
Regulators of serum calcium in health and in CKD
Hypercalcaemia is not just a result of high calcium intake.
Both low and high blood PTH levels and 1,25(OH)D (1,25
hydroxy-vitamin D) can cause hypercalcaemia. Under normal
circumstances, after calcium has been absorbed into the blood
it can be exchanged as part of bone remodelling, incorporated
into bone for growth or excreted in the urine (Fig. 1) [17]. The
plasma calcium therefore does not indicate the total body
calcium, but is a reflection of calcium movement into and
out of the extracellular fluid (ECF). Indeed, just as
hypercalcaemia does not necessarily mean that total body
calcium is in excess, normocalcaemia does not mean that it
is adequate. The ionised calcium in the ECF is crucial for the
function of many enzyme systems throughout the body and, in
particular, signalling pathways. Its maintenance within a strict,
narrow range is therefore essential. A fall in plasma ionised
calcium level activates calcium sensing receptors in the para-
thyroid gland which, in turn, activate PTH production. All of
the actions of PTH are to increase the plasma calcium level,
which it does by increasing renal tubular calcium reabsorp-
tion, increasing production of 1,25(OH)2D, which in turn
increases absorption of calcium from the gut, and by causing
an efflux of calcium from bone. Therefore, if calcium influx
from the gut is low, PTH stimulation will result in calcium
being taken from bone, and if levels rise in the blood, PTH is
suppressed and renal tubular reabsorption of calcium is de-
creased so that calcium is excreted in the urine. Prolonged,
uncontrolled PTH secretion will result in downregulation of
PTH receptors so that a higher plasma calcium level is needed
to suppress PTH, resulting in hypercalcaemia. On the other
hand, low PTH levels will result in adynamic bone that is
unable to buffer influxes of plasma calcium, also resulting in
hypercalaemia (Fig. 2). This bimodal effect is also seen with
vitamin D (Fig. 3) [18]. High 1,25(OH)2D (1,25 dihydroxy-
vitamin D; calcitriol) levels stimulate calcium absorption and
suppress PTH, whereas low levels decrease calcium absorp-
tion and increase PTH, and are also associated with higher C-
reactive protein levels.
Recent studies have also suggested that FGF23, a bone-
derived protein that was first believed to bemainly involved in
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phosphate homeostasis, is also involved in calcium regulation.
FGF23 increases renal phosphate excretion by downregulat-
ing the sodium–phosphate co-transporter in the proximal tu-
bules, thereby, at least in early CKD, increasing phosphorus
(P) excretion [19]. It also suppresses 1α-hydroxylase and
increases 24-hydroxylase activity, so that there is a reduced
production and increased degradation of 1,25(OH)2D [19].
Recent work has shown that there may be a threshold effect
of serum calcium on FGF23 regulation, such that FGF23 is
not stimulated when the calcium level is very low (essentially
because this would reduce calcitriol and further aggravate
hypocalcaemia). Studies in uraemic rats support this finding:
in the presence of hypocalcaemia FGF23 production was not
increased by low calcitriol or high PTH levels [20]. Interest-
ingly, sevelamer, but not Ca-based binders, have been shown
to decrease FGF23 levels in predialysis CKD patients, but this
effect could not be attributable to improved phosphate or 1,25
(OH)2D levels [21], suggesting that a relative hypocalcaemia
in these subjects did not allow for FGF23 production irrespec-
tive of phosphate or 1,25 (OH)2D levels. A study in
haemodialysis patients has shown that the use of higher dial-
ysate Ca concentrations, as well as the administration of
calcitriol and a calcium-based phosphate binder were associ-
ated with higher final serum FGF23 levels [22]. In a previous
study, we found that in a population of children with well-
controlled serum phosphate, high FGF23 levels were seen
with a progressive decline in estimated glomerular filtration
rate (eGFR) and showed a positive correlation with serum
calcium [23]. The complex interactions of calcium, phosphate,
vitamin D and FGF23 are shown in Fig. 4.
The need for calcium in growing bones
The growing skeleton has a high demand for calcium, whereas
adults may have ‘adynamic’ bones that are unable to
incorporate calcium [24]. Clinical measures of bone mineral
density (BMD) and bone biopsies have shown defective
mineralisation as early as CKD stage 2 [25], and the preva-
lence increases to 90% in patients on dialysis [26]. In dialysed
children, the mineralisation defect was found to persist after
treatment with active vitamin D sterols combined with either
calcium-based or calcium-free binders and were associated
with a concomitant increase in FGF23 levels [27]. Important-
ly, on bone biopsies in a cohort of 160 children on peritoneal
dialysis, the same group showed that low serum calcium and
high PTH levels were associated with defective
mineralisation, irrespective of bone turnover [28]. This find-
ing has been further corroborated by dual energy x-ray ab-
sorptiometry (DEXA) studies: BMD loss was been attributed
to low calcium and high PTH levels and was associated with
increased fracture risk [29]. In a recent study in 5- to 21-year-
olds with CKD stages 2–5, including patients on dialysis,
lower calcium levels were associated with baseline and pro-
gression of BMD loss; one standard deviation decrease in
BMD was associated with a twofold increase in fracture risk.
Adynamic bone disease has a high prevalence, being observed
in 40–50 % of adult and almost 30 % of paediatric ESKD
patients [30–32].
One factor that is often forgotten is that the normal
range for plasma calcium is highest at birth, falling pro-
gressively thereafter, but it does not reach adult values
until the age of 4 years. This may not be recognised by
clinicians (Fig. 5).
Clinical studies of the role of calcium in vascular
calcification
Converging evidence from clinical and experimental studies
suggests a role for high serum calcium levels, particularly
when associated with high phosphate levels, in the
Fig. 3 Low and high vitamin D levels would be expected to cause
ectopic calcification
Fig. 4 Mechanisms involved in calcium homeostasis. FGF-23
Fibroblast growth factor, PTH Parathyroid hormone
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development and progression of vascular calcification.
Changes in arterial structure as well as loss of compliance of
arteries have been reported as early as in the second decade of
life in children on dialysis [5, 33–39], with approximately
20 % of children on dialysis shown to have coronary artery
calcification on computed tomography (CT) scams, increased
carotid intima-media thickness (cIMT) and calcified arteries
[5, 36, 39]. Evidence of vascular calcification on CT scans is
directly related to a high serum calcium × phosphate (Ca–P)
product, serum phosphate level, intake of calcium containing
phosphate binders and plasma PTH levels [34]. In a postmor-
tem analysis of 120 children with CKD, soft tissue and vas-
cular calcification was associated with the use of active vita-
min D and calcium-containing phosphate binders [40]. Pro-
gressive increase of cIMT has been associated with higher
serum Ca–P product and PTH [5, 41, 42]. In the seminal paper
by Goodman et al., not only were the patients with coronary
artery calcification older than those without calcification, but
they also had a significantly higher mean serum Ca–P level
(5.2 vs. 4.5 mmol2/L2) and almost double the intake of calci-
um from binders (6,456 vs. 3,325 mg/day) [5]. The serum
phosphate, Ca–P and PTH levels were very high in both
patient groups, and the calcium intake from phosphate binders
was significantly above the K/DOQI (National Kidney Foun-
dation Kidney Disease Outcomes Quality Initiative) recom-
mended limit of 1,500 mg/day, suggesting that these patients
were at a substantial risk of ectopic calcification [5]. More-
over, transient increases in calcium that occur in relation to
dialysis [43] and vitamin D or binder intake may go unrecord-
ed, but these can impact on ectopic calcification, particularly
in the setting of high phosphate conditions. In the ‘Treat-to-
Goal’ study, the calcium-treated group had significantly more
hypercalcaemic episodes than the sevelamer group [8], and
the extent of arterial calcification was directly related to the
number of episodes of hypercalcaemia during the preceding
6 months [8].
Studies on the role of calcium intake, from diet, binders or
dialysate, on vascular calcification have not been performed in
children. However, it is important to remember that the pur-
pose of the calcium homeostatic system is tomaintain the ECF
calcium levels within a very tight range; consequently, serum
calcium levels are a poor, and sometimes misleading, marker
of total body calcium level. A recent study has shown that
elevated serum calcium, phosphate and Ca–P product levels,
but not dietary calcium or phosphate consumption, are asso-
ciated with increased coronary artery calcification [44].
Experimental studies of the role of calcium in vascular
calcification
Vascular calcification is an active, highly regulated process
and not merely a passive deposition of calcium and phosphate
in dead or dying cells [45]. In response to raised extracellular
calcium and phosphate levels, vascular smooth muscle cells
(VSMCs) undergo specific phenotypic changes, including
apoptosis, osteo/chondrocytic differentiation and the release
of small membrane-bound bodies called vesicles that form a
nidus for the deposition of basic Ca–P in the form of hydroxy-
apatite nanocrystals [6, 45, 46]. VSMC transformation to an
osteo/chondrocytic phenotype is characterised by the upregu-
lation of bone-specific transcription factors and matrix pro-
teins, including Runx2/Cbfa1, osterix and alkaline phospha-
tase, which in turn lead to accelerated calcification [6, 47–50].
Raised serum phosphate level is a key factor that triggers
osteoblastic differentiation of the VSMC [49].
Using intact arteries from children, we have shown that
calcification in the vessel wall begins in pre-dialysis CKD
stages 4 and 5 but is significantly greater in dialysis patients,
with the calcium load in the vessel wall increasing linearly
with time on dialysis and strongly correlated with the mean
time-averaged serum Ca–P product [6]. When these vessel
rings were cultured in graded concentrations of calcium and
phosphate, normal and pre-dialysis vessels were resistant to
calcification, but dialysis vessels showed accelerated calcifi-
cation in high calcium and phosphate media [51]. The syner-
gistic effect of the Ca–P product in driving calcification may
be related to hydroxyapatite nanocrystal formation and their
lysosomal degradation, leading to very high intracellular cal-
cium levels and apoptotic cell death [52]. Also, Ca–P
nanocrystals upregulate bone proteins, including bone mor-
phogenetic protein 2 (BMP-2) and osteopontin [53, 54]. Cal-
cium plays a key role in inducing apoptosis and in the forma-
tion and release of hydroxyapatite-ladenmatrix vesicles: when
VSMCs in vitro are incubated in high calcium conditions,
apoptotic cell death releases more calcium, which in turn
may drive further apoptosis [55]. Apoptotic bodies form a
nidus for calcification, and the propensity of these to calcify
is markedly increased after calcium and phosphate treatment
Fig. 5 Normal range for calcium throughout childhood. SD Standard
deviation
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[56, 57]. Thus, once a nidus of calcification forms in the
extracellular matrix of VSMCs, its uptake and phagocytosis
will promote further calcification. Importantly, in the presence
of a high phosphate level, even a small increase in calcium in
the culture medium significantly increases calcification, and
experiments have confirmed that calcium is a key mediator of
VSMC damage and calcification [51].
Calcium balance in health
In health terms, calcium balance is a measure of the calcium
ingested and used for bone remodelling, minus the amount
removed in urine and lost in stool. In adults who are not
deficient in calcium or vitamin D, about 30 % of dietary
calcium is absorbed, and the balance would be expected to
be neutral [58]. In contrast, children require a positive calcium
balance to allow for growth, particularly during periods of
rapid bone accumulation, i.e. infancy and puberty.
Gastrointestinal calcium absorption
Calcium is absorbed mainly in the upper intestine by both
passive paracellular diffusion and by vitamin D-dependent
active transport. The first step of the active transport process
also involves passive diffusion into the enterocytes via the
TRPV6 calcium channel. The next step is 1,25(OH)2D bind-
ing to vitamin D receptors in enterocytes, thereby increasing
expression of the calcium transporter protein calbindin and
facilitating calcium transport through the cell. The third step is
transport into the ECF against a concentration gradient. This
step requires energy, in the form of calcium ATPase or
sodium/calcium exchange. If calcium intake is normal, the
majority of the absorption of calcium is by the active vitamin
D-dependent pathway [59].
Intestinal calcium absorption may, therefore, be impaired
by low calcium intake and low levels of vitamin D. Passive
absorption is dependent on the concentration gradient between
the intestinal calcium and the ECF. Intestinal calcium absorp-
tion is also reduced by other gut contents which may bind it,
such as phytate and oxalate, and by steroids and magnesium
deficiency [60]. In healthy children with a low dietary calcium
intake, a greater proportion is absorbed (approximately 34%),
and the calcium level is proportional to circulating 25(OH)D
levels. In healthy children with higher dietary calcium
intakes, vitamin D has less of an influence on calcium
absorption, and proportionately less calcium is absorbed
(approximately 29 %), i.e. there is adaptation to low
25(OH)D levels and dietary calcium intake [60, 61]. What
is not yet known is what proportion of calcium is absorbed
at very high calcium intakes.
Calcium requirements throughout life
The vast majority of the total body calcium (99 %) is in the
skeleton, with 0.6 % in soft tissues and 0.1 % in the ECF [10].
There is a progressive increase in total skeletal calcium
throughout life, from approximately 25 g at birth to 900 and
1,200 g in adult women and men, respectively. Calcium
balance, therefore, needs to be positive throughout childhood.
However, the amount of calcium that can be incorporated into
the skeleton has a threshold above which any increase in
dietary calcium has no further effect. This threshold is influ-
enced by age, such that during periods of rapid growth, i.e.
infancy and adolescence, calcium balance is at its most posi-
tive. Table 1 illustrates this and clearly shows the very high
calcium requirements in the first year of life. Requirements
decrease considerably when growth has finished [60, 62].
Calcium balance in CKD
Diet, calcium and vitamin D
The anorexia of CKD and a diet prescribed to provide a low
protein and phosphate intake is very likely to have a low
calcium content as well. Furthermore, high-density feeds
may be necessary in children on dialysis who need a reduced
feed volume with extra protein to allow for losses in the
dialysate. The solubility of such feeds may decrease the ab-
sorption of minerals [63]. In addition, vitamin D deficiency is
present in 60–80% of children with CKD, even in pre-dialysis
CKD children, due to the following possibilities (1) children
with CKDmay be less active with, consequently, less sunlight
exposure; (2) the endogenous synthesis of vitamin D in the
skin is known to be reduced in CKD; (3) ingestion of foods
that are natural sources of vitamin D may be reduced; (4)
proteinuria may be accompanied by high urinary losses of
vitamin D binding protein, leading to increased renal losses of
all vitamin D metabolites; (5) a low calcium diet can lead to a
depletion of vitamin D stores, as the resultant hyperparathy-
roidism will lead to a rapid conversion of 25 (OH)D to active
Table 1 Calcium intake above which no further incorporation of
calcium into bone occurs and calcium balance per day at different ages
[62]
Age (years) Calcium threshold (mg/day) Balance per day (mg/day)
0–1 1,090 503±91
2–8 1,390 246±126
9–17 1,480 396±164
18–30 957 114±133
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metabolites [64, 65]. Whether replacement of nutritional vita-
min D in CKD can improve calcium absorption is less clear. A
randomised controlled trial (RCT) of children with pre-
dialysis CKD has shown a delay in the development of hy-
perparathyroidism in those treated with ergocalciferol l [64].
In contrast, a study of adults on haemodialysis who had very
low calcium absorption values at baseline did not show any
improvement with cholecalciferol supplementation that raised
25 (OH)D levels to 50 ng/mL. The authors of this study
suggest some possible explanations: (1) vitamin D and PTH
receptor expression are downregulated by low 1,25(OH)2D
and/or high PTH so that much higher 1,25(OH)2D and PTH
concentrations are required to achieve calcium absorption than
could be achieved by reasonable cholecalciferol supplemen-
tation and/or (2) there is inhibition of calcium absorption
because of some condition specific to uraemia (e.g. metabolic
acidosis) [66].
True calcium balance studies are difficult to conduct, and
very few such studies are reported in the literature. In a 3-
week, crossover, calcium balance study of eight adults with
CKD 3 and 4 randomised to receive either no calcium car-
bonate or 1,500 mg/day, patients were in neutral balance
during the placebo phase and positive calcium balance during
the supplemented phase. There was no benefit to the phos-
phorus balance. Oral and intravenous 45calcium demonstrated
net bone balance, but less than overall calcium balance, sug-
gesting that some calcium was deposited in soft tissues [67].
This is the most powerful evidence to date of calcium reten-
tion in CKD.
Sodium bicarbonate, proton pump inhibitors and iron
As well as diet, medications used in children with CKD may
affect calcium absorption. For the passive diffusion of calcium
from the ileum and jejunum into the ECF, the calciummust be
in solution. The first step depends on calcium salt dissolution
in the acid pH of the stomach. However, when food contents
move into the duodenum, the intestinal mucosa needs protec-
tion from the acid and so bicarbonate is secreted. This in-
creases the local gut content of CO3
2− so that if the concen-
tration of calcium and carbonate exceeds the solubility limit,
intestinal precipitation of CaCO3will occur and affect both the
phosphate binding capacity of calcium-containing phosphate
binders and the absorption of calcium, i.e. calcium will pre-
cipitate as CaCO3 if the calcium concentration and the CO3
2−
is high [68]. The commonest diagnosis in young children with
CKD is CAKUT (congenital anomalies of the kidney and
urinary tract). Such children often lose bicarbonate through
the renal tubules even on dialysis and need large doses of oral
sodium bicarbonate.
Anything that increases the pH in the stomach will there-
fore affect calcium salt dissolution and decrease calcium ab-
sorption. A study of calcium absorption from CaCO3 in those
with achlorhydria compared to controls showed that the
amount of calcium absorbed was higher in the normal subjects
due to the need for a low pH to dissolve the tablets [69]. In
patients on proton pump inhibitors, calcium absorption has
been reported to be as low as 3.5 % [70]. Many children with
CKD are treated with such drugs.
Phosphate binders must be given with food andmust not be
given at the same time as iron preparations as they form
insoluble compounds in the gut.
Body compartments and calcium balance in children
on dialysis
In contrast to the healthy state, there are extra dimensions in
CKD that affect calcium balance. During dialysis there may be
either a net gain from or loss into dialysate, depending on the
concentration gradient between the calcium in the blood and
that in the dialysate. If influx into the ECF exceeds the body’s
capacity to remove it, such as if calcium cannot be excreted in
the urine because of reduced urine output (as in some patients
with CKD stage 5), or cannot be taken up by the bone
exchangeable pool, it has to go somewhere and so may be
deposited in the blood vessel wall or in soft tissues. The
dynamics of the interchangeable calcium pool on bone that
buffers changes in plasma calcium in the blood is incomplete-
ly understood, but it seems to be different from the cell-
mediated process that is required for growth [17] (Fig. 1).
Intestinal cell shedding leads to an obligatory loss of calci-
um in stool. This is particularly important in low-birth-weight
infants in whom faecal calcium excretion is greater than
urinary excretion, at 15.5±8.9 mg/kg/day (7.2±4.1 % of
intake), with some studies reporting even higher values [71].
It is not known when this changes to the lower adult values of
2 mg/kg/day.
Suggested calcium intakes in CKD
In order to try to prevent the deposition in soft tissues of
absorbed calcium that might be surplus to need, the K/DOQI
nutritional guidelines recommend restricting the upper limit of
calcium intake in CKD to <2 × the dietary reference intake,
which is less than the upper limit recommended for normal
children in those aged less than 8 years and at the upper limit
of 2,500 mg for children exceeding that age (Table 2) [72].
The K/DOQI nutritional guidelines also state that ‘the chal-
lenge is to ensure that an adequate calcium intake is achieved’,
recommending calcium supplementation for infants with
CKD, who may not get adequate amounts of calcium if not
breast fed, if low-electrolyte infant formulas are required or if
fluids are restricted, and for children and adolescents on
dialysis in whom a phosphate-restricted diet results in a
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serious calcium deficit, when typically the dietary calcium
intake is <500 mg per day. Calcium-containing phosphate
binders may then be the primary source of elemental calcium
in the diet.
The need to restrict calcium intake from binders has to be
balanced against the potential for inadequate provision of
dietary calcium. K/DOQI does acknowledge, however, that
‘There are no data on calcium retention as a function of
increased long-term calcium intake in patients with CKD,
and it is impossible to accurately assess the actual absorption
of calcium derived from binders, which is in large part depen-
dent upon the kind and amount of food present in the stomach
with the binder’ [10]. These calcium intake guidelines have
recently been approved by the K/DOQI nutrition group [11].
How much calcium is absorbed from CaCO3 and calcium
acetate?
The amount of calcium that is absorbed from a dose of
calcium-containing phosphate binder is unknown. It is likely
to vary between individuals and according to dietary protein,
phosphate, fibre and sodium intake, the vitamin D prescription
and when the binder is taken in relationship to food.
CaCO3 is most soluble at pH 1–3 and binds to phosphate
best at pH >5, with very little binding below that. . Short-term
studies in adults have shown that for a given dose of elemental
calcium, calcium acetate binds twice as much phosphate at the
same dose of elemental calcium as CaCO3 and, therefore, less
calcium is absorbed. One meal balance study showed that the
ratio of milligrams phosphate bound to milliequivalents calci-
um absorbed was 6.8 with calcium acetate and 2.5 for CaCO3.
However, long-term studies of CaCO3 versus calcium acetate
have just looked at the difference in the incidence of
hypercalcaemia between the two drugs, and this has given
variable results [73].
Pa t ien ts on convent iona l th ree - t imes-a -week
haemodialysis or peritoneal dialysis are those who have the
most problems with hypercalcaemia due to calcium-
containing phosphate binders because of their reduced ability
to excrete calcium in the urine. However, the most common
cause of CKD in childhood is CAKUT, so many children are
not oliguric and continue to produce urine volumes appropri-
ate to their fluid intake; consequently, calcium restriction is
less necessary. Use of calcium neutral dialysate (1.25mmol/L)
allows for the prescription of larger doses of calcium.
Calcium absorption is greater if the binder is taken be-
tween—rather than with—meals, to prevent it acting as a
calcium supplement. Absorption will also vary with plasma
1,25(OH)2D levels, being as low as 3% in the deficiency state
to presumably higher than the expected normal range in
patients who are prescribed activated vitamin D, when
hypercalcaemia may occur.
Clinical trials of phosphate binders
The long-term cardiovascular effects of phosphate binder
therapy remain controversial. A recent randomised clinical
trial in adults with a GFR of 20–45 ml/min/1.73 m2 demon-
strated an increase in arterial calcification in those patients
receiving calcium, lanthanum and sevelamer binder therapy,
but not in the placebo-treated patients [74]. Another study
showed progressive arterial calcification in predialysis pa-
tients on a low-phosphorus diet alone; progression was less
in CaCO3-treated patients and absent in sevelamer-treated
patients [75]. The Independent trial demonstrated improved
survival in predialysis patients randomised to sevelamer as
compared to those treated with CaCO3 [9, 76]. In adult dial-
ysis patients, sevelamer was also found to reduce the progres-
sion of coronary artery calcifications, but not to be associated
with reduced mortality [77]. However, what has clinched the
demise of calcium-based phosphate binders in adults is a
recent meta-analysis of 11 RCTs, with 2,312 patients on
non-calcium-based phosphate binders and 2,310 patients tak-
ing calcium-based phosphate binders. There was a 22 % re-
duction in all-cause mortality in the non-calcium group. A
subanalysis of seven RCTs (704 patients) in which vascular
calcification had been measured showed that non-calcium
based binders resulted in less progression of vascular calcifi-
cation [78].
Recent studies in adults have shown that a regimen based
on a combination of sevelamer + calcium-based binders was
capable of effectively managing hyperphosphataemia without
hypercalcaemia at reduced financial burden [79]. The average
dose of sevelamer was 2.8 g per day, which is substantially
lower than the average daily dose (6.5 g) in the study of
Chertow et al. [8]. The combination therapy was better toler-
ated and showed higher patient compliance than CaCO3 or
sevelamer monotherapy [80]. In haemodialysis patients this
combination therapy averted both the hypercalcaemia of
CaCO3 and the adverse effects of sevelamer hydrochloride
Table 2 Kidney Disease Outcomes Quality Initiative guidelines for
calcium restriction in chronic kidney disease [10]
Age Dietary
reference
intake (mg)
Upper limit of calcium
intake for normal
children (mg)
Upper limit of
calcium intake in
CKD (mg)
0–6 months 210 ND ≤420
7–12 months 270 ND ≤540
1–3 years 500 2500 ≤1,000
4–8 800 2500 ≤1,600
9–18 1,300 2500 ≤2,500
CKD Chronic kidney disease, ND not defined
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when each was used as monotherapy [81]. Also, provided
patients took their prescribed total daily dose of binders, it
did not matter if different phosphate binders were taken at the
same meal or at separate ones, according to their preference
[82].
Only two studies have examined calcium acetate versus
sevelamer in children. In an 8-week crossover study in chil-
dren, sevelamer and calcium acetate were equally effective at
reducing serum phosphate levels, but significantly less
hypercalcaemia occurred in the sevelamer group [83]. In the
second study, bone biopsies suggested that the sevelamer
group had reduced bone formation at the 8-month follow-up,
but the numbers were too small for comparison [26]. Without
evidence, clinical practice is highly variable, with many ne-
phrologists using sevelamer, which is the more expensive
option and little is known about its long-term effects in
children.
What new phosphate binders will soon be available
for children?
The ideal phosphate binder would be one that has a high
affinity for phosphate, is long acting with a small tablet load,
has an acceptable taste and texture and is without side effects,
is not absorbed, can be administered down a feeding tube and
is inexpensive. No phosphate binder that is currently available
fulfils all of these criteria. The problem is the increased cost
associated with non-calcium-containing binders, which has a
substantial effect on prescribing budgets, although this may
change when patents expire.
Colestilan
Colestilan (MCI-196) is an anion exchange resin that
absorbs bile acids and phosphorus in the gastrointestinal
tract. The absorption of bile acids has a lipid-lowering
effect as well, particularly serum low-density lipoprotein
cholesterol. In addition to tablets it is available as
granules that can either be swallowed or administered
via an enteral feeding tube. Trials in adults are complete
and are ongoing in children.
Iron-based binders
The use of iron-based phosphate binders is attractive as there
are the potential additional advantages of providing iron and
being calcium-free. In a randomised, placebo controlled trial
of adult haemodialysis patients, ferric citrate controlled phos-
phorus compared with placebo with comparable safety pro-
files. Patients on ferric citrate required less intravenous iron
and less erythropoietin-stimulating agent [84]. Trials are due
to start in children.
Conclusion
It cannot be assumed that calcium intake is adequate in all
children with CKD, and the amount of calcium absorbed from
phosphate binders is unknown. Studies of phosphate binders
in adults should not be extrapolated to children: children need
a positive calcium balance for healthy bone growth, the spec-
trum of causal diseases are different and, in particular, urine
output is often not impaired even on dialysis.
Careful assessment of calcium intake is required in children
with CKD to ensure that calcium intake is adequate but not in
excess. Studies are needed to explore calcium absorption from
calcium-containing binders.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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